Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
15:18 MIN
  • CIDP
  • GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
DOWNLOAD PDF
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
15:31 MIN
  • CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
DOWNLOAD PDF
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Jeffrey A. Allen, MD
University of Minnesota
12:50 MIN
  • CIDP
  • MMN
Review options for individualizing treatment and tools used to assess IgG performance
DOWNLOAD PDF
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
9:35 MIN
  • CIDP
  • MMN

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

DOWNLOAD PDF
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
12:50
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Review options for individualizing treatment and tools used to assess IgG performance
NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

Our Experts on CIDP

Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
  • CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Incidence of GBS and CIDP Following Influenza Vaccination
PDF | 155 KB
Wear-Off in IVIG and What it Means in Clinical Practice
PDF | 
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
PDF | 1.4 MB
Back to Top